Abstract
We know that sleep problems often occur in patients with PD, such as difficulty in falling asleep, difficulty in maintaining sleep, etc. However, as a key indicator of sleep maintenance insomnia, sleep fragmentation is the most common complaint of sleep.
Risk factors for poor sleep include various physical diseases, female, poor sleep habits, life stress events, etc. Similarly, there are different sleep risk factors in Parkinson’s disease. In addition to the motor symptoms associated with PD, such as tremor, stiffness, leg spasm and dystonia, sleep disorders associated with PD are also very common, such as primary sleep disorders, psychophysiological insomnia (independent of the disease), RLS/PLMD, vivid dreams/nightmares and obstructive sleep apnoea (OSA).
Studies have confirmed that the insomnia of PD patients is related to many factors, among which the severe motor and non-motor symptoms are more closely related. Therefore, the quality of life of patients is obviously affected.
Existing evidence supports that the treatment of insomnia with PD is considered insufficient. Controlled-release carbidopa-levodopa, eszopiclone and melatonin 3–5 mg were considered acceptable risks without special monitoring. Although there is limited evidence to support the treatment of other psychiatric disorders that may lead to insomnia, the treatment of insomnia for specific psychiatric symptoms, such as anxiety, depression and hallucinations, is worth considering in clinical trials.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641–9.
Abdulla AJJ, Pearce VR. The nighttime problems of Parkinson’s disease. Clin Neuropharmacol. 1988;11:512–9.
Ylikoski A, Martikainen K, Partinen M. Parkinson’s disease and restless legs syndrome. Eur Neurol. 2015;73:212.
Erro R, Santangelo G, Picillo M, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol. 2012;259:1808–13.
Shafazand S, Wallace DM, Arheart KL, et al. Insomnia, sleep quality, and quality of life in mild to moderate Parkinson’s disease. Ann Am Thorac Soc. 2017;14:412–9.
Seockhoon C, Bohnen NI, Albin RL, Frey KA, Müller MLTM, Chervin RD. Insomnia and sleepiness in Parkinson disease: associations with symptoms and comorbidities. J Clin Sleep Med. 2013;9:1131–7.
Chahine LM, Daley J, Horn S, et al. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:859–63.
Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson’s disease. Parkinsonism Relat Disord. 2016;33:51–7.
Videnovic A, Willis GL. Circadian system—a novel diagnostic and therapeutic target in Parkinson’s disease? Mov Disord. 2016;31:260–9.
Sherif E, Valko PO, Overeem S, Baumann CR. Sleep benefit in Parkinson’s disease is associated with short sleep times. Parkinsonism Relat Disord. 2014;20:116–8.
Dhawan V, Healy DG, Pal S, Chaudhuri KR. Sleep-related problems of Parkinson’s disease. Age Ageing. 2006;35:220–8.
Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord. 2014;29:195–202.
Verbaan D, Van-Rooden SM, Visser M, Marinus J, Van-Hilten J. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2010;23:35–41.
Marinus J, Zhu K, Marras C, Aarsland D, van Hilten J. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17:559–68.
Schrempf W, Brandt MD, Storch A, Reichmann H. Sleep disorders in Parkinson’s disease. J Parkinsons Dis. 2014;4:211–21.
Rodrigues TM, Castro CA, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord. 2016;27:25–34.
MD PM-MP, Fabrizio Stocchi MD, FRCP KSM, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2010;22:1623–9.
Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015;30:1451–60.
Tekriwal A, Kern DS, Tsai J, et al. REM sleep behaviour disorder: prodromal and mechanistic insights for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2016;88:445–51. https://doi.org/10.1136/jnnp-2016-314471.
Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12:443–53.
Abbott SM, Videnovic A. Chronic sleep disturbance and neural injury: links to neurodegenerative disease. Nat Sci Sleep. 2016;8:55.
Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354:1004–8.
Wallace DM, Shafazand S, Carvalho DZ, et al. Sleep-related falling out of bed in Parkinson’s disease. J Clin Neurol. 2012;8:51.
Garcia-Borreguero D, Larrosa O, Bravo M. Parkinson’s disease and sleep. Sleep Med Rev. 2003;7:115–29.
Elise Tandberg MD, Larsen JP, Karen Karlsen MD. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord. 1998;13:895.
Abel T, Havekes R, Saletin JM, Walker MP. Sleep, plasticity and memory from molecules to whole-brain networks. Curr Biol. 2013;23:R774–88.
Patti CL, Zanin KA, Sanday L, et al. Effects of sleep deprivation on memory in mice: role of state-dependent learning. Sleep. 2010;33:1669.
Yaffe K, Falvey CM, Hoang T. Connections between sleep and cognition in older adults. Lancet Neurol. 2014;13:1017–28.
Van Someren EJ, Cirelli C, Dijk DJ, Van CE, Schwartz S, Chee MW. Disrupted sleep: from molecules to cognition. J Neurosci. 2015;35:13889–95.
Luik AI, Zuurbier LA, Direk N, Hofman A, Van Someren EJ, Tiemeier H. 24-hour activity rhythm and sleep disturbances in depression and anxiety: a population-based study of middle-aged and older persons. Depress Anxiety. 2015;32:684–92.
Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord. 2012;27:617–26.
Iranzo A, Valldeoriola F, Santamaría J, Tolosa E, Rumià J. Sleep symptoms and polysomnographic architecture in advanced Parkinson’s disease after chronic bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry. 2002;72:661–4.
Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Curr Neurol Neurosci Rep. 2009;9:263.
Martinez-Martin P, Visser MB, Rodriguez-Blazquez C, Marinus J, Chaudhuri K, Van-Hilten J. SCOPA-sleep and PDSS: two scales for assessment of sleep disorder in Parkinson’s disease. Mov Disord. 2010;23:1681–8.
Shukla AW, Brown R, Heese K, et al. High rates of fatigue and sleep disturbances in dystonia. Int J Neurosci. 2015;126:928–35.
Trenkwalder C, Kohnen R, Högl B, et al. Parkinson’s disease sleep scale—validation of the revised version PDSS-2. Mov Disord. 2011;26:644–52.
Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM. Assessment of sleep and sleepiness in Parkinson disease. Sleep. 2003;26:1049.
Lee CN, Kim M, Lee HM, Jang JW. The interrelationship between non-motor symptoms in atypical Parkinsonism. J Neurol Sci. 2013;327:15–21.
Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens insomnia scale. J Psychosom Res. 2003;55:263–7.
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540.
Martino JT, Freelance CB, Willis GL. The effect of light exposure on insomnia and nocturnal movement in Parkinson’s disease: an open label, retrospective, longitudinal study. Sleep Med. 2018;44:24–31.
Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–40.
Ebersbach G, Hahn K, Lorrain M, Storch A. Tolcapone improves sleep in patients with advanced Parkinson’s disease (PD). Arch Gerontol Geriatr. 2010;51:e125–8.
Trosch RM, Friedman JH, Lannon MC, et al. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998;13:377–82.
Khedr EM, Farweez HM, Islam H. Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson’s disease patients. Eur J Neurol. 2015;10:567–72.
van Dijk KD, Møst EI, Van Someren EJ, Berendse HW, Yd VDW. Beneficial effect of transcranial magnetic stimulation on sleep in Parkinson’s disease &dagger. Mov Disord. 2010;24:878–84.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Hu, H., Liu, CF. (2020). Insomnia. In: Liu, CF. (eds) Sleep Disorders in Parkinson’s Disease. Springer, Singapore. https://doi.org/10.1007/978-981-15-2481-3_4
Download citation
DOI: https://doi.org/10.1007/978-981-15-2481-3_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-2480-6
Online ISBN: 978-981-15-2481-3
eBook Packages: MedicineMedicine (R0)